11 result(s)
IN VIVO
Ex VIVO
Results from Phase 2 Study of NTLA-2002 for Hereditary Angioedema
Intellia Therapeutics Sponsored Event
Results From a Phase 2, Randomized, Placebo-Controlled Trial of CRISPR-Based Therapy NTLA-2002 for Hereditary Angioedema
American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
CRISPR-Based Therapy for Hereditary Angioedema
New England Journal of Medicine
Activity of Follow-On Dosing for an Investigational In Vivo CRISPR-Based Lipid Nanoparticle Therapy in Transthyretin Amyloidosis
Peripheral Nerve Society Annual Meeting
NTLA-2002 Long-Term Phase 1 Data Update from the Ongoing Phase 1/2 Study
Intellia Therapeutics Sponsored Event
CRISPR-Based Gene Editing of KLKB1 Resulted in Long-Term Plasma Kallikrein Protein Reduction and Decreased Attack Rate in Patients With Hereditary Angioedema
European Academy of Allergy and Clinical Immunology Congress 2024
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
New England Journal of Medicine
Enabling the Development of Serum [TTR] as a Biomarker for Treatment of ATTR Amyloidosis
4th International ATTR Amyloidosis Meeting for Patients and Doctors
NTLA-2002 Interim Clinical Data Update from Ongoing First-in-Human Study
Intellia Therapeutics Sponsored Event
Updated Safety and Efficacy of NTLA-2002, a CRISPR/Cas9-based Gene Editing Therapy Targeting KLKB1, in a Phase 1 Study of Patients with Hereditary Angioedema
European Academy of Allergy and Clinical Immunology Hybrid Congress
Transient exposure to NTLA-2002, an investigational CRISPR/Cas9-based gene editing therapy, leads to durable pharmacodynamic responses and attack control in patients with hereditary angioedema
13th C1 Inhibitor Deficiency and Angioedema Workshop
